Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial - Authors' reply
- PMID: 33991474
- PMCID: PMC8115943
- DOI: 10.1016/S0140-6736(21)00894-1
Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial - Authors' reply
Conflict of interest statement
We declare patents for an immunobiological expression vector, pharmaceutical agent, and its method of use to prevent COVID-19.
Comment on
-
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2. Lancet. 2021. PMID: 33545094 Free PMC article. Clinical Trial.
References
-
- Pagotto V, Ferloni A, Soriano MM. Active surveillance of the Sputnik V vaccine in health workers. medRxiv. 2021 doi: 10.1101/2021.02.03.21251071. published online Feb 5. (preprint). - DOI
-
- Ministerio de Salud de la Provincia de Buenos Aires. Ministerio de Ciencia. Tecnología e Innovación Instituto Leloir — CONICET-INBIRS-UNLP Empleo de la vacuna Sputnik V en Argentina: Evaluación de respuesta humoral frente a la vacunación. Informe parcial Enero-Marzo 2021. March 3, 2021. https://www.argentina.gob.ar/sites/default/files/informe_sputnik_buenos_...
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
